International Expert Opinions and Recommendations on the Use of Melatonin in the Treatment of Insomnia and Circadian Sleep Disturbances in Adult Neuropsychiatric Disorders
Conclusion: The administration of prolonged release melatonin at 2–10 mg, 1–2 h before bedtime, might be used in the treatment of insomnia symptoms or comorbid insomnia in mood disorders, schizophrenia, in adults with autism spectrum disorders, neurocognitive disorders and during sedative-hypnotics discontinuation. Immediate release melatonin at <1 mg might be useful in the treatment of circadian sleep disturbances of neuropsychiatric disorders.
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
More News: Anxiety | Autism | Brain | Eating Disorders & Weight Management | Hyperactivity | Insomnia | Melatonin | Neurology | Psychiatry | Schizophrenia | Sleep Disorders | Sleep Medicine | Study